At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…
Search results for: macrophage
Precision Medicine Today: Predicting Treatment Response in Patient Subgroups
SNOWMASS VILLAGE, COLO.—Choosing the right treatment at the right time is the brass ring all rheumatologists hope for. Precision medicine provides the ability to leverage clinical, biomarker and omics data to predict and personalize future treatment for rheumatoid arthritis (RA). “New data and new methods to analyze the data are helping us better predict patterns…
The Latest Advances in Sjögren’s, Scleroderma, RA, Gout & More
ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…
2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses
In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…
Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts
ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…
Don’t Forget the Host: COVID-19 Cytokine Storm
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.
Remembering Etanercept & the Advent of the Biologic Era
As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…
Myositis-Specific Antibodies Identified
The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…
Fall 2019’s Awards, Appointments & Announcements in Rheumatology
J. Michelle Kahlenberg Receives Presidential Early Career Award for Scientists & Engineers (PECASE) A physician scientist and associate professor of internal medicine in the Division of Rheumatology at the University of Michigan in Ann Arbor, J. Michelle Kahlenberg, MD, PhD, is a 2019 recipient of the prestigious PECASE award. Dr. Kahlenberg, who also holds the…
Pediatric Rheumatology Learning at the 2019 ACR/ARP Annual Meeting
At this year’s ACR/ARP Annual Meeting, Nov. 8–13, all of the pediatric rheumatology sessions will take place in the same room, making it easy to access all of the exciting content. Planners hope this convenient setup facilitates networking before and after symposia. “In pediatric rheumatology, we are very tight-knit community. This [event] is our opportunity…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 27
- Next Page »